Milestone Pharmaceuticals, Inc. (MIST)
0.8097
-0.01
(-0.74%)
USD |
NASDAQ |
Oct 02, 16:00
0.8036
-0.01
(-0.75%)
After-Hours: 20:00
Milestone Pharmaceuticals Enterprise Value : 72.03M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 72.03M |
| October 01, 2026 | 72.78M |
| September 30, 2026 | 79.00M |
| September 29, 2026 | 73.31M |
| September 28, 2026 | 70.25M |
| September 25, 2026 | 69.38M |
| September 24, 2026 | 70.19M |
| September 23, 2026 | 78.54M |
| September 22, 2026 | 85.89M |
| September 21, 2026 | 85.49M |
| September 18, 2026 | 85.24M |
| September 17, 2026 | 85.71M |
| September 16, 2026 | 81.93M |
| September 15, 2026 | 86.72M |
| September 14, 2026 | 89.42M |
| September 11, 2026 | 93.24M |
| September 10, 2026 | 101.95M |
| September 09, 2026 | 104.44M |
| September 08, 2026 | 111.28M |
| September 04, 2026 | 120.62M |
| September 03, 2026 | 121.87M |
| September 02, 2026 | 118.13M |
| September 01, 2026 | 113.15M |
| August 31, 2026 | 115.64M |
| August 28, 2026 | 115.64M |
| Date | Value |
|---|---|
| August 27, 2026 | 119.38M |
| August 26, 2026 | 118.13M |
| August 25, 2026 | 115.64M |
| August 24, 2026 | 100.70M |
| August 21, 2026 | 102.57M |
| August 20, 2026 | 99.46M |
| August 19, 2026 | 105.68M |
| August 18, 2026 | 104.44M |
| August 17, 2026 | 108.17M |
| August 14, 2026 | 108.17M |
| August 13, 2026 | 104.44M |
| August 12, 2026 | 111.28M |
| August 11, 2026 | 129.34M |
| August 10, 2026 | 128.09M |
| August 07, 2026 | 123.11M |
| August 06, 2026 | 118.13M |
| August 05, 2026 | 113.77M |
| August 04, 2026 | 116.89M |
| August 03, 2026 | 110.66M |
| July 31, 2026 | 109.42M |
| July 30, 2026 | 114.40M |
| July 29, 2026 | 100.70M |
| July 28, 2026 | 104.44M |
| July 27, 2026 | 111.91M |
| July 24, 2026 | 115.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| InMed Pharmaceuticals, Inc. | 4.867M |
| NervGen Pharma Corp. | 128.24M |
| Clearmind Medicine, Inc. | -12.60M |
| Lexaria Bioscience Corp. | 0.8348M |
| Target Group, Inc. (Canada) | 11.59M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.61M |
| Revenue (Quarterly) | 0.559M |
| Total Expenses (Quarterly) | 29.17M |
| EPS Diluted (Quarterly) | -0.2063 |
| Gross Profit Margin (Quarterly) | 84.08% |
| Profit Margin (Quarterly) | -5.12K% |
| Earnings Yield | -85.69% |
| Normalized Earnings Yield | -85.69 |